Business, energy, technology, markets and global industry news from Business News Today

Vanda Pharmaceuticals Inc.

PharmaDeviceNews Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals advances imsidolimab for generalized pustular psoriasis after a positive European Medicines Agency orphan drug recommendation, although approval and commercialisation hurdles remain. Representative image.
Pharma & Biotech

Vanda’s imsidolimab has won a rare European advantage, but one approved rival changes the equation

Vanda’s imsidolimab gains an EMA orphan recommendation for GPP, but approval, differentiation and European access remain ahead.

Read More
Representative image: A ferry passenger experiencing motion sickness, reflecting Vanda Pharmaceuticals Inc.’s U.S. launch of NEREUS as a new prescription treatment option for adults with vomiting induced by motion.
Pharma & Biotech

Can direct to consumer access help Vanda scale NEREUS beyond niche travel use?

Motion sickness finally has a new prescription drug. Vanda’s test is whether NEREUS can move beyond travel novelty into real demand.

Read More
Vanda Pharmaceuticals secures milsaperidone approval, but bipolar I disorder and schizophrenia uptake remains uncertain
Pharma & Biotech

FDA approval of milsaperidone puts Vanda Pharmaceuticals into crowded bipolar I disorder and schizophrenia markets

FDA approves milsaperidone for bipolar I disorder and schizophrenia. Explore what this means for psychiatry, competition, and Vanda Pharmaceuticals’ strategy.

Read More